What is NDC 83257-035?

83257-035 is the product NDC for Yesafili (aflibercept-jbvf), Aflibercept 2 mg/.05mL injection, solution, listed with the FDA by Biocon Biologics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.

Biocon Biologics Inc., NDC labeler code 83257. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Yesafili?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Yes: J0178, Injection, aflibercept, 1 mg.

Yesafili NDC 83257-035 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)83257-035Labeler and product segments. Claims need a package NDC.

Product NDC at billing width83257-0035Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
83257-035-41	8325700354183257003541	1 SYRINGE, GLASS in 1 CARTON (83257-035-41) / .05 mL in 1 SYRINGE, GLASSMarketed from Aug 3, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Yesafili
Generic name (nonproprietary): aflibercept-jbvf
Active ingredients: Aflibercept — 2 mg/.05mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Biocon Biologics Inc.NDC labeler code 83257
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761274
Marketing start: Aug 3, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 83257-035_783e32b7-6349-2a90-55c2-9e040cfe854eSPL ID 783e32b7-6349-2a90-55c2-9e040cfe854e
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0178 — Injection, aflibercept, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

EYLEA HD and aflibercept biosimilars have their own HCPCS codes.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N483257003541 followed by a unit qualifier and the quantity

Package 83257-0035-41. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 83257-035

What is NDC 83257-035?: 83257-035 is the product NDC for Yesafili (aflibercept-jbvf), Aflibercept 2 mg/.05mL injection, solution, listed with the FDA by Biocon Biologics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Yesafili (Aflibercept-jbvf).
What is the active ingredient?: Aflibercept.
Who is the labeler?: Biocon Biologics Inc., NDC labeler code 83257. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Yesafili?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Yes: J0178, Injection, aflibercept, 1 mg. See Billing references above.

Yesafili (Aflibercept-jbvf) NDC 83257-035